<DOC>
	<DOCNO>NCT00281996</DOCNO>
	<brief_summary>RATIONALE : Imatinib mesylate may stop growth tumor cell block enzymes need cell growth . Drugs use chemotherapy , gemcitabine , work different way stop growth tumor cell , either kill cell stop divide . Giving imatinib mesylate together gemcitabine may kill tumor cell . PURPOSE : This phase I/II trial study side effect best dose give imatinib mesylate together gemcitabine see well work treat patient locally advance , metastatic , recurrent pancreatic cancer .</brief_summary>
	<brief_title>Imatinib Mesylate Gemcitabine Treating Patients With Locally Advanced , Metastatic , Recurrent Pancreatic Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine maximum tolerate dose imatinib mesylate gemcitabine hydrochloride patient locally advance , metastatic , recurrent pancreatic cancer . - Determine clinical response rate patient treat regimen . - Determine 6-month overall survival patient treat regimen . Secondary - Determine toxicity profile regimen patient . - Correlate response expression platelet-derived growth factor ( PDGF ) PDGF receptor tumor tissue patient treat regimen . OUTLINE : This phase I , dose-escalation study follow phase II study . - Phase I : Patients receive oral imatinib mesylate daily day 1-14 gemcitabine hydrochloride IV 30 minute day 1 8* . Treatment repeat every 21 day 6 course absence disease progression unacceptable toxicity . Cohorts 3-5 patient receive escalate dos imatinib mesylate gemcitabine hydrochloride maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 5 3 5 patient experience dose-limiting toxicity . NOTE : *The first cohort receives gemcitabine hydrochloride day 1 , 8 , 15 - Phase II : Patients receive imatinib mesylate gemcitabine hydrochloride MTD determine phase I absence disease progression unacceptable toxicity . After completion study treatment , patient follow periodically . PROJECTED ACCRUAL : A total 43 patient accrue study .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm pancreatic cancer Locally advance , metastatic , recurrent disease Measurable evaluable disease physical exam , plain radiograph , CT scan , MRI No brain metastasis PATIENT CHARACTERISTICS : ECOG performance status 02 Life expectancy 12 week great Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Bilirubin ≤ 1.5 time upper limit normal ( ULN ) AST ≤ 2.5 time ULN ( 5 time ULN liver metastasis present ) No chronic liver disease ( i.e. , chronic active hepatitis cirrhosis ) Creatinine ≤ 2.0 mg/dL No chronic renal disease Not pregnant nursing Negative pregnancy test Fertile patient must use effective barriermethod contraception ≥ 3 month completion study treatment No malignancy within past 5 year except basal cell skin cancer carcinoma situ cervix No uncontrolled diabetes No active uncontrolled infection No severe and/or uncontrolled medical disease HIV negative PRIOR CONCURRENT THERAPY : No prior therapy metastatic disease Prior fluorouracil radiosensitizer adjuvant therapy surgery locally advance disease permit local disease recur progressed ≥ 3 month completion therapy disease present outside radiation field At least 2 week since prior major surgery No concurrent grapefruit grapefruit juice</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>recurrent pancreatic cancer</keyword>
	<keyword>stage III pancreatic cancer</keyword>
	<keyword>stage IV pancreatic cancer</keyword>
</DOC>